Risks of Biogen Alzheimer's Drug Are Clear, but Its Benefits Are Still Unproven, Says Raymond James

·

·

Risks of Biogen Alzheimer's Drug Are Clear, but Its Benefits Are Still Unproven, Says Raymond James

The stock rose after company scientists presented a new analysis of Alzheimer’s drug tests that management thinks will convince regulators that the treatment works. The stock rose after company scientists presented a new analysis of Alzheimer’s drug tests …
See Original Article

Firms giving back: Protiviti donates ten millionth meal

Global consulting firm Protiviti donates its ten millionth meal as part of its “i on Hunger” program; Dixon Hughes Goodman donates $48K to the
See Original Article

Big Lots shares surge as third-quarter results top estimates

Big Lots shares surged Friday morning after the retailer reported a third-quarter adjusted loss that came in better than analyst estimates. The closeout retailer said it earned $127 million, or $3.25 per share, for the period that ended Nov. 2. The profit was tied to …
See Original Article

Ex-Celadon Execs Accused of Accounting Fraud

The former chief operating officer and former CFO of Celadon have been charged with orchestrating an accounting fraud that enabled the trucking
See Original Article

Tesla Stock Could Be Worth $500, but Don't Buy It, Analyst Says

Wall Street prefers earnings to hype. Analysts’ price targets on Tesla stock moved much more in response to the company’s third-quarter earnings than they did after the launch of the Cybertruck pickup, even though the truck garnered about 250,000 orders in …
See Original Article



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.